Doxorubicin conjugates for selective delivery to tumors.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Topics in current chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/128_2007_12PMID 23605630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin.

  2007cited by this paper
• Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo

  2006cited by this paper
• A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.

  2006cited by this paper
• Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.

  2006cited by this paper
• A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs

  2006cited by this paper
• Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers

  2006cited by this paper
• Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors

  2006cited by this paper
• Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA.

  2006cited by this paper
• A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers.

  2006cited by this paper
• Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin.

  2006cited by this paper
• Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).

  2006cited by this paper
• Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

  2006cited by this paper
• Pros and Cons of the Liposome Platform in Cancer Drug Targeting

  2006cited by this paper
• Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice.

  2005cited by this paper
• In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model.

  2005cited by this paper
• Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues

  2005cited by this paper
• Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.

  2005cited by this paper
• Single-triggered trimeric prodrugs.

  2005cited by this paper
• Arming antibodies: prospects and challenges for immunoconjugates

  2005cited by this paper
• Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.

  2005cited by this paper
• Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner]

  2005cited by this paper
• Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

  2005cited by this paper
• Targeting therapeutic and imaging agents to folate receptor positive tumors.

  2005cited by this paper
• Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.

  2005cited by this paper
• Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.

  2005cited by this paper
• Legumain Expression in Relation to Clinicopathologic and Biological Variables in Colorectal Cancer

  2005cited by this paper
• Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 can overcome chemoresistance in experimental renal cell carcinomas

  2005cited by this paper
• Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.

  2005cited by this paper
• Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.

  2005cited by this paper
• Folate receptor-mediated drug targeting: from therapeutics to diagnostics.

  2005cited by this paper
• Monoclonal antibody–drug conjugates

  2005cited by this paper
• Minireview. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1

  2005cited by this paper
• Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.

  2005cited by this paper
• Matrix metalloproteinase–activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity

  2005cited by this paper
• Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1

  2005cited by this paper
• A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy

  2005cited by this paper
• Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.

  2005cited by this paper
• Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238

  2005cited by this paper
• A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.

  2004cited by this paper
• Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9.

  2004cited by this paper
• Pronounced Antitumor Efficacy by Extracellular Activation of a Doxorubicin-Glucuronide Prodrug After Adenoviral Vector-Mediated Expression of a Human Antibody-Enzyme Fusion Protein

  2004cited by this paper
• Tumor-activated Prodrugs—A New Approach to Cancer Therapy

  2004cited by this paper
• Bacteriolytic therapy can generate a potent immune response against experimental tumors.

  2004cited by this paper
• Folate receptor targeted biodegradable polymeric doxorubicin micelles.

  2004cited by this paper
• Folate receptor-targeted drugs for cancer and inflammatory diseases.

  2004cited by this paper
• Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.

  2004cited by this paper
• Chemical adaptor systems.

  2004cited by this paper
• Tumour-selective drug delivery via folate receptor-targeted liposomes

  2004cited by this paper
• Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate.

  2004cited by this paper
• Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

  2004cited by this paper
• Enzyme-Catalyzed Activation of Anticancer Prodrugs

  2004cited by this paper
• LEAPT: lectin-directed enzyme-activated prodrug therapy.

  2004cited by this paper
• Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.

  2004cited by this paper
• Analysis and pharmacokinetics ofN-l-leucyldoxorubicin and metabolites in tissues of tumor-bearing BALB/c mice

  2004cited by this paper
• Plasmin‐activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity

  2004cited by this paper
• Geometric disassembly of dendrimers: dendritic amplification.

  2003cited by this paper
• Folate Conjugated Doxorubicin-Loaded Membrane Vesicles for Improved Cancer Therapy

  2003cited by this paper
• PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.

  2003cited by this paper
• Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

  2003cited by this paper
• Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.

  2003cited by this paper
• Targeting Doxorubicin to Epidermal Growth Factor Receptors by Site-Specific Conjugation of C225 to Poly(L-Glutamic Acid) Through a Polyethylene Glycol Spacer

  2003cited by this paper
• A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.

  2003cited by this paper
• Self-immolative dendrimers.

  2003cited by this paper
• "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core.

  2003cited by this paper
• BR96–DOX Immunoconjugate Targeting of Chemotherapy in Brain Tumor Models

  2003cited by this paper
• Targeting of Human Squamous Carcinomas by SPA470-doxorubicin Immunoconjugates

  2003cited by this paper
• Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.

  2003cited by this paper
• BR96 conjugates of highly potent anthracyclines.

  2003cited by this paper
• Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.

  2003cited by this paper
• Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.

  2003cited by this paper
• CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

  2002cited by this paper
• Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.

  2002cited by this paper
• Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains.

  2002cited by this paper
• Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.

  2002cited by this paper
• A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug

  2002cited by this paper
• Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.

  2002cited by this paper
• Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

  2002cited by this paper
• Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages.

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.

  2001cited by this paper
• Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.

  2001cited by this paper
• PDEPT: polymer-directed enzyme prodrug therapy

  2001cited by this paper
• Doxorubicin-peptide conjugates overcome multidrug resistance

  2001cited by this paper
• PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.

  2001cited by this paper
• Matrix metalloproteinases: they're not just for matrix anymore!

  2001cited by this paper
• Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates.

  2001cited by this paper
• Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.

  2001cited by this paper
• Combination bacteriolytic therapy for the treatment of experimental tumors

  2001cited by this paper
• Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX‐GA3 in combination with a monoclonal antibody β‐glucuronidase conjugate

  2001cited by this paper
• Technology evaluation: SGN-15, Seattle Genetics Inc.

  2001cited by this paper
• New functions of stromal proteases and their inhibitors in tumor progression.

  2001cited by this paper
• Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.

  2001cited by this paper
• N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.

  2001cited by this paper
• The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

  2001cited by this paper
• Selective tumor sensitization to taxanes with the mAb‐drug conjugate cBR96‐doxorubicin

  2001cited by this paper
• Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

  2000cited by this paper
• Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826).

  2000cited by this paper
• Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

  2000cited by this paper
• A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

  2000cited by this paper
• Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.

  2000cited by this paper

• Transferrin-Bound Doxorubicin Enhances Apoptosis and DNA Damage through the Generation of Pro-Inflammatory Responses in Human Leukemia Cells

  2020cites this paper
• Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors.

  2016cites this paper
• Associating Drugs with Polymer Nanoparticles: A Challenge

  2016cites this paper
• Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.

  2016cites this paper
• Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins

  2015influential citation
• A degradable brush polymer-drug conjugate for pH-responsive release of doxorubicin

  2015cites this paper
• Title : Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells under Hypoxic Conditions Short running title : Synthesis and in vitro effects of CBZ-AAN-Dox

  2015cites this paper
• Rapid and ultrasensitive electrochemical detection of multidrug-resistant bacteria based on nanostructured gold coated ITO electrode.

  2014cites this paper
• Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.

  2014cites this paper
• Polymer–Drug Nanoconjugates

  2013cites this paper
• Targeted Prodrugs of a Novel Platform Anthracycline: Doxazolidine

  2012influential citation
• Development of a Gd(III)-based receptor-induced magnetization enhancement (RIME) contrast agent for β-glucuronidase activity profiling.

  2012cites this paper
• Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide).

  2012cites this paper
• Possibilities to increase the effectiveness of doxorubicin in cancer cells killing

  2011influential citation
• Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.

  2011cites this paper
• Anticancer prodrugs: an overview of major strategies and recent developments.

  2011cites this paper
• Development of capillary electrophoretic-based techniques to analyze doxorubicin in tissues, cells and subcellular fractions.

  2010cites this paper
• Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles.

  2009cites this paper
• Recent Advances in Protection against Doxorubicin-induced Toxicity

  2008cites this paper